MCM
PCRX icon

Massar Capital Management’s Pacira BioSciences PCRX Stock Holding History

Massar Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,500
Closed -$211K – 160
2025
Q1 		$211K Buy
+8,500
New +$203K 0.24% 84

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Massar Capital Management's PCRX Position: Q2 2025 in Review

Massar Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2025, closing a stake of 8,500 shares — an estimated $211K sold.

Massar Capital Management first reported a position in PCRX in Q1 2025 and held it in 1 quarter. The position peaked at $211K in Q1 2025. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

  • Massar Capital Management reported no remaining Pacira BioSciences position as of Q2 2025 after selling out during the quarter.
  • Massar Capital Management sold 8,500 Pacira BioSciences shares in Q2 2025, an estimated $211K.
  • Massar Capital Management first reported a position in Pacira BioSciences in Q1 2025 and held it in 1 quarter.
  • Massar Capital Management's Pacira BioSciences position peaked at $211K in Q1 2025.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on Massar Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.